Actively Recruiting
Personalized NK Cell Therapy in CBT
Led by M.D. Anderson Cancer Center · Updated on 2026-05-05
100
Participants Needed
1
Research Sites
575 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.
CONDITIONS
Official Title
Personalized NK Cell Therapy in CBT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have a hematologic malignancy such as acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin's disease, or multiple myeloma
- Patients with AML must meet specific high-risk or induction failure criteria
- MDS patients include those with intermediate or high-risk disease, transfusion dependency, or progression despite treatment
- ALL patients must have induction failure, refractory disease, or be beyond first remission with high-risk features
- NHL patients should be in second or third remission or relapse, including relapsed double hit lymphomas
- SLL or CLL patients must have progressive disease after at least two lines of therapy
- CML patients must be in second chronic or accelerated phase
- Hodgkin's disease patients must have induction failure, relapse, or active disease
- Multiple myeloma patients must have stage II or III symptomatic disease requiring treatment
- A back-up source of cord blood or donor must be identified
- Age between 15 and 45 years for myeloablative regimen, or 15 to 80 years for nonmyeloablative or reduced intensity regimens
- Karnofsky performance score of 60% or higher
- Adequate heart function with left ventricular ejection fraction of at least 40% (or 30% for nonmyeloablative regimen)
- Pulmonary function showing diffusion capacity of at least 50% predicted
- Kidney function with creatinine clearance or GFR above 40 mL/min/1.73 m²
- Liver enzymes (SGPT/bilirubin) below specified limits depending on regimen
- Negative pregnancy test for women of childbearing potential
- Patients with known curative treatment options are not eligible
- Enrollment on other supportive care investigational new drug studies allowed at investigator discretion
You will not qualify if you...
- Positive for human immunodeficiency virus (HIV)
- Uncontrolled serious medical conditions such as ongoing severe infections, heart failure not controlled by medication, pulmonary insufficiency requiring breathing support, or psychiatric conditions limiting consent
- Active central nervous system disease in patients with a history of CNS malignancy
- Availability of an appropriate, willing human leukocyte antigen (HLA)-matched related stem cell donor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
A
Amanda Olson, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here